The World Market for Molecular Diagnostics Tests, 11th Edition

    Published: November 3, 2022 | Price: $6,000.00 – $12,000.00

    Kalorama Information’s 11th Edition report of the clinical molecular testing industry provides marketing sizing and forecasts for in vitro diagnostics (IVDs) over a five-year period. In this report, our industry experts and top analysts assess the current positions of this complex market, which has an estimated value of more than $21 billion. This data publication has become an indispensable tool in clinical healthcare medicine and assesses the business opportunity, new product introductions, and rapid changes in several areas of this...
    The World Market for Molecular Diagnostics Tests, 10th Edition (NGS, PCR, NAAT, ISH, TMA, Other)

    Published: June 17, 2021 | Price: $5,000.00 – $10,000.00

    Molecular diagnostics is a fast evolving and dynamic field and is the fastest growing segment within the in vitro diagnostics (IVD) market. It has become an indispensable tool in clinical medicine that touches all aspects of healthcare including treatment decisions in terms of identifying antimicrobial resistant (AMR) infections at the earliest, companion diagnostics assisting in the evaluation of suitability of various cancer treatment options, pharmacokinetics or patient metabolism of drugs for HIV, psychiatric conditions or blood thinners; cancer prognosis and...
    The World Molecular Diagnostics Market, 8th Edition

    Published: June 6, 2019 | Price: $4,000.00 – $8,000.00

    Molecular diagnostics is a fast evolving and dynamic field and is the fastest growing segment within the in vitro diagnostics (IVD) market. It has become an indispensable tool in clinical medicine that touches all aspects of healthcare including treatment decisions in terms of identifying antimicrobial resistant (AMR) infections at the earliest, companion diagnostics assisting in the evaluation of suitability of various cancer treatment options, pharmacokinetics or patient metabolism of drugs for HIV, psychiatric conditions or blood thinners; cancer prognosis and...